Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D C Gilbert

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 5, 2016
Initial Results from the Royal College of Radiologists' UK National Audit of Anal Cancer Radiotherapy 2015R Muirhead, K Drinkwater, S M O'Cathail, et al.
European Journal of Cancer (Oxford, England : 1990)|February 29, 2020
UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomesA Gilbert, K Drinkwater, L McParland, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 9, 2017
Comprehensive Geriatric Assessment in Men Aged 70 Years or Older with Localised Prostate Cancer Undergoing Radical RadiotherapyG E C Osborne, S A Appleyard, D C Gilbert, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|May 24, 2021
Multicentre Investigation of Prognostic Factors Incorporating p16 and Tumour Infiltrating Lymphocytes for Anal Cancer After ChemoradiotherapyK Wakeham, L Murray, R Muirhead, et al.
ESMO Open|January 5, 2023
Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugsJ K Overbeek, R Ter Heine, H M W Verheul, et al.
ESMO Open|July 11, 2022
A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)S Rao, G Anandappa, J Capdevila, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2025
Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems dataC Jones, P Dutey-Magni, L R Murphy, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 16, 2023
A Repurposing Programme Evaluating Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial DesignD C Gilbert, M Nankivell, H Rush, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2018
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocolM R Sydes, M R Spears, M D Mason, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 5, 2016
Initial Results from the Royal College of Radiologists' UK National Audit of Anal Cancer Radiotherapy 2015R Muirhead, K Drinkwater, S M O'Cathail, et al.
European Journal of Cancer (Oxford, England : 1990)|February 29, 2020
UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomesA Gilbert, K Drinkwater, L McParland, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 9, 2017
Comprehensive Geriatric Assessment in Men Aged 70 Years or Older with Localised Prostate Cancer Undergoing Radical RadiotherapyG E C Osborne, S A Appleyard, D C Gilbert, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|May 24, 2021
Multicentre Investigation of Prognostic Factors Incorporating p16 and Tumour Infiltrating Lymphocytes for Anal Cancer After ChemoradiotherapyK Wakeham, L Murray, R Muirhead, et al.
ESMO Open|January 5, 2023
Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugsJ K Overbeek, R Ter Heine, H M W Verheul, et al.
ESMO Open|July 11, 2022
A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)S Rao, G Anandappa, J Capdevila, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2025
Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems dataC Jones, P Dutey-Magni, L R Murphy, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 16, 2023
A Repurposing Programme Evaluating Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial DesignD C Gilbert, M Nankivell, H Rush, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2018
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocolM R Sydes, M R Spears, M D Mason, et al.
Pageof 4